In a significant medical advancement, scientists have developed a cutting-edge breath analyzer capable of detecting minuscule blood clots that often go unnoticed. These silent blood clots can be an early indicator of various diseases and tend to worsen clinical symptoms. The innovative technique involves the analysis of exhaled air to monitor the formation of these tiny clots.
Immunothrombosis, driven by inflammation, involves the development of small clots within the body's small blood vessels. Ali Hafezi-Moghadam, an associate professor at Harvard Medical School, highlighted the importance of this research, stating, "Early in the pandemic, pathologists reported from autopsies that microthrombotic events in the lung's microvessels caused significant morbidity."
The lack of technology to detect these events non-invasively prompted the development of this groundbreaking technique. Immunothrombosis can lead to severe complications, including fatality, in individuals with conditions such as sepsis, heart disease, and diabetes, extending beyond its relevance in the context of Covid-19.
This pioneering research not only offers a way to measure thrombin activity non-invasively but also holds promise for early detection of various other conditions, including cancer, neurodegeneration, and lung fibrosis. Breath analysis presents an economical, non-invasive, and easily repeatable method for diagnosing and screening various medical conditions.
Ali Hafezi-Moghadam, the lead scientist behind this work, envisions a future where a simple breath sample could provide precise information about enzymatic activity profiles in the body. Such a development could revolutionize early diagnosis and significantly improve the prognosis of conditions like fibrosis, cancer, and metabolic complications through timely interventions.
The key to this breakthrough is the detection of thrombin, an enzyme critical in blood clot formation. At present, there is no technology available to measure the activity of thrombin within a living organism. To bridge this gap, the research team devised a non-invasive approach that relies on analyzing exhaled gases to identify thrombin as an indicator of systemic immunothrombosis.
The technique involves the use of nanoprobes designed to be sensitive to thrombin. These dendritic nanoprobes consist of branched structures with molecules that can detect thrombin's enzymatic activity, along with a volatile molecule. When thrombin interacts with the nanoprobe within the body, it triggers the cleavage of a peptide, releasing a gas-like volatile molecule. These liberated gas molecules travel to the lungs and become detectable in the breath.
Researchers measured the exhaled gas molecules using gas-chromatography mass-spectral analysis, a technique that identifies substances based on their molecular weight. Additionally, they developed nanoprobes with fluorescence molecules for lab experiments, allowing for visual confirmation of thrombin activity.
The researchers conducted tests on mouse models of immunothrombosis, using both types of nanoprobes. The results confirmed the effectiveness of the nanoprobes in detecting thrombin activity, both visually and through exhaled breath measurements.
